Aetion is a real-world evidence (RWE) healthcare analytics platform that applies advanced causal inference, epidemiologic methods, and AI to transform healthcare data into transparent, reliable evidence on the safety, effectiveness, and value of medical treatments. The Aetion Evidence Platform powers decision-making for biopharma companies, payers, and regulatory agencies. Serves 40+ leading biopharma organizations and 80+ data partners.
Aetion has been acquired
This company is no longer available on our private secondary market.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2013
Employees
200–250
Total Funding
$203.6M
5 rounds
Total raised $203.6M across 5 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series C
Date
May 13, 2021
Amount
$110M
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| May 13, 2021 | Series C | $110M | — | Warburg Pincus |
| August 2020 | Series B extension (Aug 2020) | $19M | — | Not disclosed |
| 2019 | Series B extension (strategic) | $27M | — | Not disclosed |
Jeremy Rassen
Chief Executive Officer
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Flatiron Health
Oncology-focused real-world data and AI platform acquired by Roche
IQVIA
Contract research organization and real-world data analytics provider
Veradigm
Health intelligence platform with electronic health record data
TriNetX
Real-world data exchange network for clinical research and drug development
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.